MS patients treated with rituximab may receive COVID-19 vaccine as soon as possible

Rituximab-treated patients with MS may be vaccinated for COVID-19 as soon as possible, researchers reported in JAMA Network Open.
Andreas Tolf, MD, of the department of medical sciences at Uppsala University in Sweden, and colleagues conducted a prospective cohort study from Jan. 21 to Dec. 1, 2021, and analyzed data from 67 participants with planned or ongoing treatment with rituximab.
Researchers assessed serological vaccine responses by measuring quantitation of anti-spike IgG antibodies and anti-receptor-binding domain (RBD) IgG antibodies, as well as their neutralizing capacities.
Among the

Rituximab-treated patients with MS may be vaccinated for COVID-19 as soon as possible, researchers reported in JAMA Network Open.
Andreas Tolf, MD, of the department of medical sciences at Uppsala University in Sweden, and colleagues conducted a prospective cohort study from Jan. 21 to Dec. 1, 2021, and analyzed data from 67 participants with planned or ongoing treatment with rituximab.
Researchers assessed serological vaccine responses by measuring quantitation of anti-spike IgG antibodies and anti-receptor-binding domain (RBD) IgG antibodies, as well as their neutralizing capacities.
Among the